CELLINK and IISc collaborate to advance research in 3D bioprinting

The Centre of Excellence will be focused on advancing research across heart, bone, cartilage and cancer research through the use of 3D bioprinting.

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

The Centre of Excellence will be focused on advancing research across heart, bone, cartilage and cancer research through the use of 3D bioprinting.

CELLINK, a global leader in developing 3D bioprinters and The Indian Institute of Science (IISc) are partnering to establish a Centre of Excellence for 3D bioprinting in Bengaluru, India.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LTUI: 2093

CELLINK

Longevity level(s):

  • Level 7: Targeted aging disease reversal
    Therapeutic interventions that stop or reverse age-related damage in specific organs (organ specific / tissue specific / localized reversal) or for age-related diseases including technologies like partial cellular reprogramming.
  • Level 9: Organ/organism preservation or maintenance
    Companies developing technologies to replace or repair damaged organs and tissues, effectively halting or reversing the physical manifestations of aging ahead of the availability of systemic aging reversal (Level 8) interventions. Includes xenotransplantation, bionic organs, and 3D organ printing.

Overview

CELLINK is a leading 3D bioprinting company that develops and commercializes advanced bioprinting technologies, bioinks, and biomaterials for life science research and regenerative medicine applications. The company provides extrusion-based and light-based bioprinters, including the BIO X, BIO X6, LUMEN X, BIONOVA X, and BIO ONE platforms, alongside a comprehensive portfolio of bioinks designed for tissue engineering, drug discovery, and personalized medicine. CELLINK's technology enables researchers to create three-dimensional tissue models that more accurately replicate in vivo environments, accelerating drug development and reducing reliance on animal testing. The company serves over 1,600 academic, pharmaceutical, and industrial laboratories globally and has been cited in more than 1,000 peer-reviewed publications. CELLINK operates as a division of BICO Group, a Swedish bioconvergence company focused on advancing biology research through integrated technology platforms.

Access all data points on DLT:

  • Financial Data
  • Patents
  • Technology
  • Management
  • Advisory Board
  • News
  • Classifications
  • Similar Companies
Expand

Eleanor Garth

Editor

Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

With a keen interest in all things geroscience, Eleanor covers the biological mechanisms of aging, highlighting how interventions – from nutritional strategies to advanced therapeutics – can influence the aging process at a cellular level. She also investigates the broader implications of aging research, including the integration of longevity science into healthcare strategy and the expanding wellness economy. Her work (hopefully) provides insights into how these developments are shaping the emerging landscape of healthspan optimization and age-related innovation.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Oyster surfaces with $60m and a tau degrader that travels light

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE